Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
NewTimeSpace News: On June 30, 2026, Ascletis Pharma(01672.HK) issued a voluntary announcement stating that the Board has resolved to exercise the share repurchase mandate and conduct share repurchases on the open market from time to time in light of market conditions, with a proposed maximum aggregate repurchase amount of HK$300 million.
The Company stated that all repurchases will comply with the terms of the repurchase mandate, the Listing Rules and applicable laws and regulations, and will not cause the public float to fall below the statutory minimum percentage. Repurchased shares may subsequently be cancelled, held as treasury shares, sold or transferred.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
- WK GROUP (02535.HK): Appoints Shousheng Capital as Independent Financial Adviser to Advise on Fairness and Reasonableness of the Offer
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
- Black Sesame International Holding (02533.HK): Interim Revenue Forecast to Rise by No Less Than 81.1% with Robotic Business Recording Substantial Growth
